IL1B and Alzheimer disease: Corroborating these findings, it was demonstrated that NJK14047 (selective p38α/β inhibitor) reduced NOS, COX-2, TNF-α, and IL-1β in vitro, decreased microglia activation in vivo [128], and improved cognitive functions in an AD mouse model [129].